A tiny bacterial fragment with big consequences for lung disease

Researchers at the University of Illinois Urbana-Champaign and Mie University in Japan have pinpointed a bacterial protein fragment called corisin as a direct, mechanistic driver of pulmonary fibrosis — not just a bystander. The peptide, originally identified in gut bacteria, was also found to be produced locally in the lungs by bacteria residing in the respiratory tract. Once inside lung cells, corisin accumulates in the mitochondria, disrupting protein quality control and triggering oxidative stress, premature cellular aging, and cell death — ultimately leading to scarring.

The team demonstrated that corisin extracted from patient lung fluid could kill healthy cells in culture, and that neutralizing it with a custom antibody largely prevented that damage. Mice engineered to continuously produce corisin in their lungs spontaneously developed pulmonary fibrosis — and when treated with the antibody, showed significantly reduced disease severity and improved survival.

Key Takeaways:

• Corisin-producing bacteria were detected directly in lung fluid from pulmonary fibrosis patients — a first
• Even extremely low levels of corisin were sufficient to trigger significant biological damage
• A corisin-neutralizing antibody (patent pending) reduced fibrosis and improved survival in mouse models
• The mechanism may extend beyond the lungs — fibrosis contributes to nearly half of all deaths in developed countries

Why it matters: Pulmonary fibrosis has very limited treatment options and a poor prognosis. Identifying corisin as a causally supported, targetable driver of disease offers a genuinely novel therapeutic avenue — not just for the lungs, but potentially for fibrotic diseases affecting the kidneys, liver, heart, and skin as well.